<li>aceclofenac<p>aceclofenac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>acemetacin<p>acemetacin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>albiglutide<p>albiglutide, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>alogliptin<p>alogliptin, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .</p></li><li>aluminum hydroxide<p>aluminum hydroxide will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>aripiprazole<p>aripiprazole, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>aspirin<p>aspirin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin rectal<p>aspirin rectal increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>atazanavir<p>atazanavir decreases effects of glipizide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>benazepril<p>benazepril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypogylcemic effects.</p></li><li>bexarotene<p>bexarotene increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.</p></li><li>bezafibrate<p>bezafibrate increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>bitter melon<p>bitter melon increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>calcium carbonate<p>calcium carbonate will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>canagliflozin<p>glipizide, canagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.</p></li><li>captopril<p>captopril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood glucose. Monitor blood glucose.</p></li><li>celecoxib<p>celecoxib increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cinnamon<p>cinnamon increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofibrate<p>ciprofibrate increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>ciprofloxacin<p>ciprofloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.</p></li><li>clarithromycin<p>clarithromycin increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>clotrimazole<p>clotrimazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>clozapine<p>clozapine, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>colesevelam<p>colesevelam decreases levels of glipizide by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases glipizide absorption; however, absorption is not reduced when glipizide is administered 4 hr before colesevelam.</p></li><li>dapagliflozin<p>glipizide, dapagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.</p></li><li>darunavir<p>darunavir, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Darunavir may increase or decrease levels of glipizide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>diclofenac<p>diclofenac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>diflunisal<p>diflunisal increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>disopyramide<p>disopyramide increases effects of glipizide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>dulaglutide<p>dulaglutide, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of glipizide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>empagliflozin<p>empagliflozin, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.</p></li><li>enalapril<p>enalapril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>etoricoxib<p>etoricoxib increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia. .</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia.</p></li><li>famotidine<p>famotidine will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fenofibrate<p>fenofibrate increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibrate micronized<p>fenofibrate micronized increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibric acid<p>fenofibric acid increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenoprofen<p>fenoprofen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fleroxacin<p>fleroxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>fluconazole<p>fluconazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>fluoxetine<p>fluoxetine increases effects of glipizide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>flurbiprofen<p>flurbiprofen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fosamprenavir<p>fosamprenavir, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Fosamprenavir may increase or decrease levels of glipizide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>fosinopril<p>fosinopril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>gemfibrozil<p>gemfibrozil increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>gemifloxacin<p>gemifloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ibuprofen<p>ibuprofen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>iloperidone<p>iloperidone, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>imidapril<p>imidapril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir decreases effects of glipizide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>indomethacin<p>indomethacin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>insulin aspart<p>glipizide, insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin aspart protamine/insulin aspart<p>glipizide, insulin aspart protamine/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec<p>glipizide, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec/insulin aspart<p>glipizide, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin detemir<p>glipizide, insulin detemir.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glargine<p>glipizide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glulisine<p>glipizide, insulin glulisine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin inhaled<p>glipizide, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin isophane human/insulin regular human<p>glipizide, insulin isophane human/insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro<p>glipizide, insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro protamine/insulin lispro<p>glipizide, insulin lispro protamine/insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin nph<p>glipizide, insulin nph.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin regular human<p>glipizide, insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>isocarboxazid<p>isocarboxazid increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac<p>ketorolac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac intranasal<p>ketorolac intranasal increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>levofloxacin<p>levofloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>linagliptin<p>glipizide, linagliptin. Other (see comment). Use Caution/Monitor. 
Comment: When linagliptin is used in combination with sulfonylureas, a lower dose of the sulfonylurea may be required to reduce risk of hypoglycemia.</p></li><li>linezolid<p>linezolid increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>liraglutide<p>liraglutide, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>lisinopril<p>lisinopril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>lixisenatide<p>lixisenatide, glipizide.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with sulfonylureas. Sulfonylurea dosage reduction may be required.</p></li><li>lopinavir<p>lopinavir, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Lopinavir may increase or decrease levels of glipizide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>lornoxicam<p>lornoxicam increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>lurasidone<p>lurasidone, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>marijuana<p>marijuana decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>meclofenamate<p>meclofenamate increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>mefenamic acid<p>mefenamic acid increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>meloxicam<p>meloxicam increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>metreleptin<p>glipizide, metreleptin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.</p></li><li>miconazole vaginal<p>miconazole vaginal increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>mipomersen<p>mipomersen, glipizide.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>moexipril<p>moexipril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nabumetone<p>nabumetone increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nadolol<p>nadolol decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>naproxen<p>naproxen increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nelfinavir<p>nelfinavir decreases effects of glipizide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>nitazoxanide<p>nitazoxanide, glipizide.
Either increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of glipizide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>norfloxacin<p>norfloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ospemifene<p>glipizide, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>oxaprozin<p>oxaprozin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>paliperidone<p>paliperidone, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>parecoxib<p>parecoxib increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of glipizide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>perindopril<p>perindopril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>phenelzine<p>phenelzine increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>piroxicam<p>piroxicam increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>posaconazole<p>posaconazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>probenecid<p>probenecid increases levels of glipizide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>propranolol<p>propranolol decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>quetiapine<p>quetiapine, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>quinapril<p>quinapril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ramipril<p>ramipril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ranitidine<p>ranitidine will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rasagiline<p>rasagiline increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>rifabutin<p>rifabutin decreases levels of glipizide by increasing metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin decreases levels of glipizide by increasing metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine decreases levels of glipizide by increasing metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Ritonavir may increase or decrease levels of glipizide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>salsalate<p>salsalate increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>saquinavir<p>saquinavir decreases effects of glipizide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>selegiline<p>selegiline increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic medications. Hypoglycemic effects may be increased.</p></li><li>selegiline transdermal<p>selegiline transdermal increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>shark cartilage<p>shark cartilage increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>sodium bicarbonate<p>sodium bicarbonate will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sulfadiazine<p>sulfadiazine increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>sulfamethoxazole increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of glipizide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfasalazine<p>sulfasalazine increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfisoxazole<p>sulfisoxazole increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>timolol<p>timolol decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>tipranavir<p>tipranavir decreases effects of glipizide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>tolfenamic acid<p>tolfenamic acid increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolmetin<p>tolmetin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>trandolapril<p>trandolapril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of glipizide by unknown mechanism. Use Caution/Monitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous increases levels of glipizide by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole increases levels of glipizide by decreasing metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide decreases levels of glipizide by increasing renal clearance. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li>